Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Strand Therapeutics Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. The distribution of these actions across 2 distinct art units suggests a diverse range of technical subject matter within the portfolio. Prosecution is handled by 2 distinct examiners, indicating that each examiner is responsible for a unique portion of the pending workload. This structure requires the company to navigate different examiner preferences across multiple units simultaneously.
PYLA, EVELYN Y is identified as the busiest examiner for this portfolio, currently overseeing 1 busiest examiner pending office action. This specific examiner is responsible for 1 of the 2 pending office actions currently active for the company. The presence of 2 distinct art units matches the count of 2 distinct examiners, showing that the number of examiners aligns with the number of specialized units. Having 1 busiest examiner pending action assigned to PYLA, EVELYN Y ensures that a single individual handles a significant part of the active workload. This narrow examiner pool of 2 individuals allows for a focused prosecution strategy within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PYLA, EVELYN Y | 1 | 55.7% | +47.1% |
| HASAN, KHALEDA B | 1 | 59.4% | +49.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18294799 | POLYNUCLEOTIDES AND USES THEREOF | PYLA, EVELYN Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18006555 | LIPID NANOPARTICLE COMPRISING MODIFIED NUCLEOTIDES | HASAN, KHALEDA B | 7d |
| 18294799 | POLYNUCLEOTIDES AND USES THEREOF | PYLA, EVELYN Y | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18294799 | POLYNUCLEOTIDES AND USES THEREOF | PYLA, EVELYN Y | 1633 | §102§103§112 | Non-Final OA | — | Pending | Feb 02, 2024 |
| 18006555 | LIPID NANOPARTICLE COMPRISING MODIFIED NUCLEOTIDES | HASAN, KHALEDA B | 1636 | §103 | Final Rejection | 7d | Pending | Jan 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial